Celldex Therapeutics (CLDX) Cash from Financing Activities (2010 - 2026)

Celldex Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $327000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 61.88% year-over-year to $327000.0; the TTM figure through Mar 2026 stood at $2.5 million (down 54.63% YoY), while the FY2025 annual figure was $2.4 million, down 99.46% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $327000.0, down from $1.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $436.1 million in Q1 2024, with the low at $63000.0 in Q2 2025.
• The 5-year median for Cash from Financing Activities is $694000.0 (2023), against an average of $39.2 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 62740.35% in 2024, then plunged 99.95% in 2025.
• Celldex Therapeutics' Cash from Financing Activities stood at $1.4 million in 2022, then jumped by 15482.37% to $217.4 million in 2023, then slumped by 99.82% to $386000.0 in 2024, then surged by 249.48% to $1.3 million in 2025, then slumped by 75.76% to $327000.0 in 2026.
• Business Quant data shows CLDX's Cash from Financing Activities at $327000.0 in Q1 2026, $1.3 million in Q4 2025, and $774000.0 in Q3 2025.